Unione Europea - estone - EMA (European Medicines Agency)

sanofi winthrop industrie - klopidogreeli vesiniksulfaat - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitrombootilised ained - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. ennetamine atherothrombotic ja trombembooliliste sündmuste kodade fibrillationin täiskasvanud patsientidel, kellel on kodade virvendus, kes on vähemalt üks riskifaktor veresoonkonna sündmused, ei sobi ravi koos vitamiin-k antagonistid ja kes on vähese verejooksu riski, clopidogrel on näidustatud kombinatsioonis asa ennetamise atherothrombotic ja trombembooliliste sündmuste, sealhulgas insult.

Unione Europea - estone - EMA (European Medicines Agency)

viiv healthcare b.v. - abakaviir - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - ziagen on näidustatud retroviiruste vastase kombineeritud teraapias inimese immuunpuudulikkuse viiruse (hiv) nakkuse raviks täiskasvanutel, noorukitel ja lastel. tõendamine kasu ziagen põhineb peamiselt uuringute tulemused, mis on teostatud koos kaks korda ööpäevas raviskeemi, ravi-naiivne täiskasvanud patsientide kombineeritud ravi. enne algatamist ravi abacavir, sõelumine veo eest hla-b*5701 alleeli tuleks teha kõik hiv-nakatunud patsiendil sõltumata rassilisest päritolust. abacavir ei tohi kasutada patsientidel, teadaolevalt kannavad hla-b*5701 alleeli.

Estonia - estone - Ravimiamet

qilu pharma spain s.l. - meropeneem - süste-/infusioonilahuse pulber - 1000mg 1tk

Estonia - estone - Ravimiamet

jubilant pharmaceuticals nv - esomeprasool - gastroresistentne tablett - 20mg 14tk; 20mg 7tk; 20mg 30tk; 20mg 15tk; 20mg 140tk; 20mg 98tk; 20mg 50tk; 20mg 28tk; 20mg 60tk

Estonia - estone - Ravimiamet

jubilant pharmaceuticals nv - esomeprasool - gastroresistentne tablett - 40mg 14tk; 40mg 15tk; 40mg 30tk; 40mg 28tk; 40mg 140tk; 40mg 56tk; 40mg 100tk; 40mg 90tk; 40mg 60tk

Estonia - estone - Ravimiamet

baxter holding b.v. - propofool - süste-/infusiooniemulsioon - 10mg 1ml 50ml 10tk; 10mg 1ml 50ml 1tk; 10mg 1ml 20ml 1tk; 10mg 1ml 20ml 10tk

Estonia - estone - Ravimiamet

orifarm healthcare a/s - hüdrokortisoon - salv - 10mg 1g 30g 1tk; 10mg 1g 10g 1tk

Estonia - estone - Ravimiamet

vetpharma animal health s.l. - kloprostenool - süstelahus - 75mcg 1ml 20ml 1tk

Estonia - estone - Ravimiamet

bimeda animal health limited - oksütetratsükliin - süstelahus - 200mg 1ml 100ml 1tk

Estonia - estone - Ravimiamet

jubilant pharmaceuticals nv - sildenafiil - õhukese polümeerikattega tablett - 100mg 1tk; 100mg 2tk; 100mg 8tk; 100mg 4tk